AbbVie Inc (ABBV)vsCocrystal Pharma Inc (COCP)
ABBV
AbbVie Inc
$227.23
-2.70%
HEALTHCARE · Cap: $380.57B
COCP
Cocrystal Pharma Inc
$0.96
-8.16%
HEALTHCARE · Cap: $14.20M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 27919456% more annual revenue ($62.82B vs $225,000). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
COCP
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+58.7%
Fair Value
$2.31
Current Price
$0.96
$1.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 26.9% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : COCP
The strongest argument for COCP centers on Revenue Growth. Revenue growth of 26.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : COCP
The primary concerns for COCP are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while COCP is a growth play — different risk/reward profiles.
COCP carries more volatility with a beta of 1.41 — expect wider price swings.
COCP is growing revenue faster at 26.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 23/100) and 12.4% revenue growth. COCP offers better value entry with a 58.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Cocrystal Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic viral diseases. The company is headquartered in Bothell, Washington.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?